119th Congress · introduced in the Senate · May 15, 2025
No Handouts for Drug Advertisements Act
Official title from Congress.gov
Latest action (May 15, 2025): Read twice and referred to the Committee on Finance.
View on Congress.govPolicy area: Taxation
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Finance.
Introduced in Senate
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
20 citations.
THE CAMPAIGN FOR SUSTAINABLE RX PRICING · lobbying firm or registrant: MEHLMAN CONSULTING, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Taxation/Internal Revenue Code
$90,000
Paid to lobbying firm
S. 1785/H.R. 3010 - The No Handouts for Drug Advertisements Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COALITION FOR HEALTHCARE COMMUNICATIONS · lobbying firm or registrant: COALITION FOR HEALTHCARE COMMUNICATIONS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 2, 2026 · issue area: Health Issues
Amount not reported
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · lobbying firm or registrant: WHITMER & WORRALL, LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 22, 2026 · issue area: Taxation/Internal Revenue Code
$50,000
Paid to lobbying firm
S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE CAMPAIGN FOR SUSTAINABLE RX PRICING · lobbying firm or registrant: MEHLMAN CONSULTING, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Taxation/Internal Revenue Code
$90,000
Paid to lobbying firm
S. 1785/H.R. 3010 - The No Handouts for Drug Advertisements Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COALITION FOR HEALTHCARE COMMUNICATIONS · lobbying firm or registrant: COALITION FOR HEALTHCARE COMMUNICATIONS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 6, 2026 · issue area: Health Issues
Amount not reported
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
COALITION FOR HEALTHCARE COMMUNICATIONS · lobbying firm or registrant: COALITION FOR HEALTHCARE COMMUNICATIONS
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted May 4, 2026 · issue area: Health Issues
Amount not reported
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · lobbying firm or registrant: WHITMER & WORRALL, LLC
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 21, 2026 · issue area: Taxation/Internal Revenue Code
$50,000
Paid to lobbying firm
S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CVS HEALTH (AND SUBSIDIARIES) · lobbying firm or registrant: CVS HEALTH (AND SUBSIDIARIES)
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Taxation/Internal Revenue Code
$3,320,000
Spent on own lobbying
Issues related to corporate tax. H.R. 3010/S. 1785 - No Handouts for Drug Advertisement Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE CAMPAIGN FOR SUSTAINABLE RX PRICING · lobbying firm or registrant: MEHLMAN CONSULTING, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 17, 2026 · issue area: Taxation/Internal Revenue Code
$90,000
Paid to lobbying firm
S. 1785/H.R. 3010 - The No Handouts for Drug Advertisements Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · lobbying firm or registrant: WHITMER & WORRALL, LLC
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 21, 2026 · issue area: Taxation/Internal Revenue Code
$50,000
Paid to lobbying firm
S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CVS HEALTH (AND SUBSIDIARIES) · lobbying firm or registrant: CVS HEALTH (AND SUBSIDIARIES)
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Taxation/Internal Revenue Code
$2,270,000
Spent on own lobbying
Issues related to corporate tax. H.R. 3010/S. 1785 - No Handouts for Drug Advertisement Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE CAMPAIGN FOR SUSTAINABLE RX PRICING · lobbying firm or registrant: MEHLMAN CONSULTING, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 16, 2026 · issue area: Copyright/Patent/Trademark
$90,000
Paid to lobbying firm
…58 - Medication Affordability and Patent Integrity Act. H.R. 3160/s. 1533 - the Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act. H.R. 3010/S. 1785 - the No Handouts for Drug Advertisement Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COALITION FOR HEALTHCARE COMMUNICATIONS · lobbying firm or registrant: COALITION FOR HEALTHCARE COMMUNICATIONS
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 6, 2026 · issue area: Health Issues
Amount not reported
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · lobbying firm or registrant: WHITMER & WORRALL, LLC
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Copyright/Patent/Trademark
$50,000
Paid to lobbying firm
…6 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. S.43 Skinny Labels, Big Savings Act. H.R. 5526/S. 1954, the Biosimilar Red Tape Elimination Act. S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CVS HEALTH (AND SUBSIDIARIES) · lobbying firm or registrant: CVS HEALTH (AND SUBSIDIARIES)
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Taxation/Internal Revenue Code
$2,150,000
Spent on own lobbying
Issues related to corporate tax. P.L. 119-21 - The One Big, Beautiful Bill Act H.R. 3010/S. 1785 - No Handouts for Drug Advertisement Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE CAMPAIGN FOR SUSTAINABLE RX PRICING · lobbying firm or registrant: MEHLMAN CONSULTING, INC.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 17, 2025 · issue area: Copyright/Patent/Trademark
$90,000
Paid to lobbying firm
…58 - Medication Affordability and Patent Integrity Act. H.R. 3160/s. 1533 - the Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act. H.R. 3010/S. 1785 - the No Handouts for Drug Advertisement Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COALITION FOR HEALTHCARE COMMUNICATIONS · lobbying firm or registrant: COALITION FOR HEALTHCARE COMMUNICATIONS
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Sep 18, 2025 · issue area: Health Issues
Amount not reported
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
COALITION FOR HEALTHCARE COMMUNICATIONS · lobbying firm or registrant: COALITION FOR HEALTHCARE COMMUNICATIONS
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Aug 5, 2025 · issue area: Health Issues
Amount not reported
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · lobbying firm or registrant: WHITMER & WORRALL, LLC
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 22, 2025 · issue area: Copyright/Patent/Trademark
$50,000
Paid to lobbying firm
…IL Act S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025 S.43 Skinny Labels, Big Savings Act S. 1954, the Biosimilar Red Tape Elimination Act S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act S.1040 Drug Competition Enhancement Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CVS HEALTH (AND SUBSIDIARIES) · lobbying firm or registrant: CVS HEALTH (AND SUBSIDIARIES)
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Taxation/Internal Revenue Code
$1,810,000
Spent on own lobbying
Issues related to corporate tax. P.L. 119-21 - The One Big, Beautiful Bill Act H.R. 3010/S. 1785 - No Handouts for Drug Advertisement Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing